YiChang HEC ChangJiang Pharmaceutical Co (HKG:1558) secured approval from China's National Medical Products Administration to launch Encofosbuvir Tablets (0.3g) for hepatitis C treatment, according to a Thursday filing on the Hong Kong Exchange.
The drug, used with Netanasvir Phosphate Capsules, targets hepatitis C genotypes 1, 2, 3, and 6, including cases with compensated cirrhosis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。